Insight

The use of surrogate endpoints in solid and haematological cancers

Photo from Timothée Olivier/X

Oct 8, 2024, 13:20

The use of surrogate endpoints in solid and haematological cancers

Ash Paul, Medical Director at EoE Specialised Commissioning Group, UK, shared a post on X:

“Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.”

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more

Authors: Timothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez and Vinay Prasad.

Source: Ash Paul/X

Alyson Haslam Ash Paul cancer cancer awareness cancer care Dagney Ochoa Eduardo Fernandez fight against cancer Global fight against cancer haematological cancers OncoDaily Oncology Timothée Olivier Vinay Prasad

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage